Skip to content

mRNA vaccine encoding multimerized AIV-M2e fused to MHC-II invariant chain motif and Pan-DR epitope confers protection against H9N2 virus in chickens.

Oct 2026 · Vaccine · Vol 95, pp. 129280 · 0 citations · 108 references
Medicine

Abstract

Avian influenza viruses (AIVs) remain a major threat to global poultry health and production. The risk of cross-species transmission among diverse AIV subtypes poses a significant challenge to disease control, underscoring the need for vaccines that provide broad and durable protection. However, existing inactivated and vector-based vaccines provide limited cross-subtype coverage and durable immunity against antigenically diverse AIVs. In contrast, the success of mRNA vaccines against SARS-CoV-2 has accelerated vaccine development by enabling rapid, flexible, and scalable vaccine design compared with conventional platforms. We designed an mRNA vaccine encoding four tandem repeats of the conserved influenza M2 ectodomain (4xM2e), fused to the chicken invariant chain (Ii) motif and a 13-amino-acid universal Pan-DR-binding epitope (PADRE). We hypothesized that this design would enhance anti-M2e antibody responses while promoting efficient antigen processing and CD4+ T-helper cell activation, thereby inducing systemic and mucosal immunity against AIV infection in chickens. The mRNA construct was delivered via standard lipid nanoparticles (LNPs), and vaccine efficacy was evaluated following intramuscular (IM) and intranasal (IN) administration. Our data demonstrated a modest increase in systemic and mucosal antibody responses, accompanied by enhanced T-cell proliferation and increased CD4+ and γδ+ T-cell populations. Following challenge with A/turkey/Wisconsin/1/1966/H9N2 virus, vaccinated birds exhibited significantly reduced viral shedding regardless of the route of administration. Histopathological analysis further demonstrated largely preserved pulmonary architecture with minimal inflammation, demonstrating effective maintenance of mucosal barrier integrity. To assess the cross-protective potential and functional activity of anti-M2e antibodies, we demonstrated in vitro heterosubtypic recognition of PR8/H1N1 and confirmed their functional relevance by antibody-dependent cellular cytotoxicity (ADCC). Together, our findings demonstrate that the present mRNA vaccine construct, encoding a structurally optimized multimerized M2e protein fused to PADRE and the Ii motif, represents a safe and effective vaccine strategy with the potential to confer broad protective immunity against AIV infection in chickens.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.